
Challenges in the new market place

10th International Pharmaceutical Compliance Congress and Best Practices Forum

Frank Wartenberg President Central Europe IMS HEALTH GmbH & Co. OHG




Global growth is now on an exceptional level – forecast suggests that it will not be sustained



Source: IMS Market Prognosis Oct 2015; (*) at ex-manufacturer price levels, not including rebates and discounts. Contains Audited + Unaudited data. \$US used for Argentina, Venezuela, Nigeria & Ukraine due to hyperinflation



Specialty medicines drive growth in developed regions; globally, primary care dominates



Source: IMS Health Market Prognosis, April 2015; IMS Institute for Healthcare Informatics, May 2015

3

Europe illustrates the importance of biologic therapies

2010 2011 2012 2013 2014 2015 HUMIRA HUMIRA HUMIRA LIPITOR **HUMIRA HUMIRA** HARVONI SERETIDE SERETIDE SERETIDE **ENBREL ENBREL HUMIRA** LIPITOR **ENBREL** SERETIDE HERCEPTIN SOVALDI **ENBREL ENBREL HERCEPTIN HERCEPTIN** SERETIDE **ENBREL HERCEPTIN** HERCEPTIN MABTHERA REMICADE REMICADE **HERCEPTIN** MABTHERA **MABTHERA AVASTIN** LOVENOX REMICADE AVASTIN LOVENOX **MABTHERA** LOVENOX **AVASTIN AVASTIN MABTHERA MABTHERA AVASTIN** REMICADE LOVENOX LYRICA REMICADE **AVASTIN** LUCENTIS LOVENOX LOVENOX ZYPREXA SPIRIVA

Top 10 Products in Europe 2010-2015

1


2

4

3 4 5 6 7 8 9 REMICADE SYMBICORT SOVALDI 10 LYRICA LYRICA SERETIDE No. Biologics 7 7 7 8 7 7 in Top 10 Small molecule Biologica Small molecule specialty product

Source: IMS Health, MIDAS, MAT Q4 2015 . Rx only. Europe excludes Russia and Turkey

There is a high concentration of spending to Top 50 products across Europe



Source: IMS Health, MIDAS Restricted, MAT Q4 2010-Q4 2015 . Rx only. Europe excludes Russia and Turkey

5

imshealth^{*}

.

EU5

High-cost products like Sovaldi influence decision-makers in their reimbursement strategy

NHS England delayed Sovaldi's introduction by 4 months; this is unprecedented


Agreement to refund the cost of Sovaldi for any patient not cured; this type of agreement is **not common** in France

MSSSI set population maximum expenditure caps for each recent innovative HCV launch separately (€125m/year for Sovaldi) Confidential discount with some sick funds prior to the GKV-SpV negotiation oucome, which is **ground-breaking** German government attempts to set a **revenue threshold** for the first year of free-pricing at €250m

AIFA set up an ad hoc fund of €750m to treat a maximum of 50.000 patients with Sovaldi in 2015

Sovaldi only the first of several potential tsunamis


Are these innovations sustainable?





... and Cell & Gene Therapies are arriving soon


Cell & Gene Therapy – Major companies are now actively engaged



Source: IMS Health Thought Leadership analysis March 2015; IMS Health Pharma Deals; deal values incl. milestones

imshealth


A restricted funding environment challenges Pharma to demonstrate value



imshealth^{*}


Challenges in Europe are numerous and uncertain





imshealth

In the EU, there is a move towards harmonizing (technical assessments



- Provide HTA advice to define relevant evidence and try to accelerate time to access
- Stakeholders discuss the planned development early, including **patient populations**, **comparators, trial design, endpoints**

Currently, EUnetHTA started phase 3 which aims to put joint assessments into real life

Joint Action 1 (2010-2012)

- Put into practice an effective and sustainable HTA collaboration in Europe
- Attempt to lower barriers for collaboration
- Deliver context specific reporting of HTA results, e.g. new application of the HTA Core Model

Joint Action 2 (2013-2015)

- Strengthen the practical application of tools and approaches to crossborder HTA collaboration
- Establish a sustainable structure for HTA in the EU
- Bringing collaboration to a higher level resulting in better understanding
- 15 joint assessments were performed during EUnetHTA JA2 (2012-2015)

Joint Action 3 2016 - 2019

- Defining and implementing a sustainable model for scientific and technical cooperation on HTA in Europe
- Results of the pilot joint assessments need to be put into the "real life" routine HTA production processes of the EUnetHTA participating organizations.

Coordinator: Danish Health Authority

Coordinator: Zorginstituut Nederland (ZIN)

imshealth

Source: EUnetHTA website



imshealth^{*}

Question is... is value defined in the same way?


Selection of oncology products: HTA assessment ratings

Brand name		-		
	HAS	GBA	NICE	Positive*
Jevtana	ASMR III	2	×	- unanimol agreemer
Halaven	ASMR IV	4	×	
Yervoy	ASMR IV	1	✓	*ASMR or GBA rating of 3 or lowe has been classed positive
Zytiga	ASMR III	1	\checkmark	
Zelboraf	ASMR III	1	\checkmark	
Inlyta	ASMR IV	2	\checkmark	
Xalkori	ASMR III	3	×	
Perjeta	ASMR III	3	×	
Tafinlar	ASMR V	5	\checkmark	
Xtandi	ASMR III	1	\checkmark	
Zaltrap	ASMR V	-	×	
Erivedge	ASMR IV	4	×	
Kadcyla	AMSR II	1	×	
Opdivo	ASMR III	1	\checkmark	
Keytruda	ASMR II	1	\checkmark	
Stivarga	AMSR IV	4	×	

Source: HTA body websites



In most EU countries only ~70-90% of the top 200 selling products are available in the market



Availability of EU Top 200 Products across Countries


Source: IMS Health MIDAS. 2015.

14 © 2016, IMS HEALTH – Dr. Frank Wartenberg (Twutter: @FrankWartenberg)

Launch rollouts of innovations across EU5 diverge greatly: Germany is key

Top 5 onco drugs (launched 2011-2015), delay from 1st country's launch, EU5


EU5



Source: IMS Health, MIDAS December 2015, Rx only. Delay calculated from 1st country's launch in one of the EU5 markets. Country ranked by months of delay since first launch; drugs ranked by sales in EU5. Imbruvica not launched yet in Spain (the 18 months equal the time between first launch and April '16) **ims**health

© 2016, IMS HEALTH – Dr. Frank Wartenberg (Twutter: @FrankWartenberg)

Looking at innovative anti-diabetics shows very (large country differences in uptakes



Europe: Uptake of Innovative Anti-diabetics (DDD/100,000 people) 2015

Many factors can affect uptake :

- GDP per capita and the financial situation of the country (high medium low income countries)
- Regional decision makers


16

- Price premium versus existing treatment
- Stakeholder attitude to innovation
- If innovation is funded by the public or private payer

Source: IMS Health MIDAS 2015. Population figures from Eurostat. * OECD health accounts data. June 2012




Important biologics already lost or are about to lose exclusivity in the near future



Source: IMS MIDAS, Q4 2015, only Rx, IMS Health analysis

© 2016, IMS HEALTH – Dr. Frank Wartenberg (Twutter: @FrankWartenberg)


The entrance of biosimilars leads to a decrease in prices – putting the originator under pressure




Source: IMS Health (2015): The Impact of Biosimilar Competition

© 2016, IMS HEALTH – Dr. Frank Wartenberg (Twutter: @FrankWartenberg)

- The increased competition affects not just the price for the directly comparable product but also the price of the whole product class
- The countries with the highest reduction show reduction of 50-70%
- Caveat prices used in the study are list prices. It can be assumed that additional discounts have been agreed in certain situations



imshealth^{*}




Source: IMS Health 2014 European Trends in Aggregate Spend, Transparency & Disclosure

© 2016, IMS HEALTH – Dr. Frank Wartenberg (Twutter: @FrankWartenberg)

imshealth

Obtaining consent is key, however status updates show that it is often missing



Source: IMS Health: 2015 European Aggregate Spend, Transparency and Disclosure, 2016 EUROPEAN USER GROUP MEETING

20


imshealth







© 2016, IMS HEALTH – Dr. Frank Wartenberg (Twutter: @FrankWartenberg)



Please contact me for more information:

Dr. Frank Wartenberg

President Central Europe, IMS Health Telefon: 069/6604-4315 <u>FWartenberg@de.imshealth.com</u>

Follow me on

Twitter: 🔰 @FrankWartenberg



imshealth Intelligence applied.

© 2016, IMS HEALTH GmbH & Co. OHG

All rights reserved. The information may not be duplicated, stored, further processed, nor be made accessible in whole or in part to any third party without the prior express written consent of IMS HEALTH.

In connection with data/figures used terms, such as "patient, doctor, medical practice, prescriber or pharmacy", do not designate any personal data but exclusively anonymous information (in accordance with § 3 Abs. 6 "Bundesdatenschutzgesetz" – German Federal Data Protection Act)

IMS employs high sophisticated technologies and methods which ensure all its Information Services to meet the applicable data-protection requirements, regardless the way data are combined with one another.

